固定剂量利福喷丁-异烟肼(1HP)在中国成人结核病预防治疗中的前瞻性真实世界安全性与药代动力学研究
该前瞻性研究在深圳结核病转诊中心纳入136例非HIV成人结核感染者,评估固定剂量1HP方案。治疗完成率为76.5%,不良事件发生率26.5%,仅1.5%发生≥3级事件。利福喷丁中位浓度21.8 mg/L,91.9%参与者超过10 mg/L阈值,提示固定剂量1HP在中国成人中耐受性良好且暴露充足。
要点
- 固定剂量1HP治疗完成率为76.5%(104/136;95%CI 68.7%-82.8%)。
- 不良事件发生率26.5%,最常见中性粒细胞减少(14.7%)和皮疹(6.6%)。
- ≥3级不良事件仅1.5%(2/136),均见于合用甲氨蝶呤者。
核心结论
- 固定剂量1HP在中国成人结核感染者中耐受性良好,完成率可接受。
- 药代动力学结果证实研究体重范围内利福喷丁暴露充足,支持固定剂量1HP方案推广。
研究设计与样本
- 前瞻性研究,在深圳结核病转诊中心纳入136例非HIV成人结核感染者,体重42-90 kg,入组时间2024年10月至2025年7月。
- 所有参与者接受固定剂量1HP方案。
主要发现
- 治疗完成率76.5%(104/136;95%CI 68.7%-82.8%),完成定义为40天内服药≥23剂。
- 不良事件发生率26.5%,最常见中性粒细胞减少(14.7%)和皮疹(6.6%);≥3级事件仅1.5%(2/136),均见于合用甲氨蝶呤者。
- 利福喷丁中位浓度为21.8 mg/L(IQR 14.8-28.4),91.9%参与者超过模型 informed 的10 mg/L阈值。
- 体重与利福喷丁浓度呈弱负相关(ρ=-0.24;P=.005),仅解释7.1%的个体间变异。
临床怎么用
- 固定剂量1HP可作为中国成人结核感染预防治疗的可行选择,尤其适用于体重42-90 kg者。
- 治疗期间应关注中性粒细胞减少和皮疹,合用甲氨蝶呤者需警惕≥3级不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization recommends 1 month of daily rifapentine plus isoniazid (1HP) for tuberculosis preventive treatment (TPT). Real-world safety and feasibility data remain scarce, particularly for East Asian populations, and the performance of fixed-dose 1HP in routine clinical practice requires prospective evaluation. METHODS: We conducted a prospective study at a tuberculosis referral center in Shenzhen, China, enrolling 136 non-human immunodeficiency virus adults (body weight 42-90 kg) with tuberculosis infection between October 2024 and July 2025. All participants received fixed-dose 1HP. Outcomes included treatment completion (defined as taking ≥23 doses within 40 days), adverse events graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and 12-hour postdose rifapentine concentrations measured by liquid chromatography-tanden mass spectrometry. RESULTS: Treatment completion reached 76.5% (104/136; 95% confidence interval [CI], 68.7%-82.8%). Adverse events occurred in 26.5% of participants, most commonly neutropenia (14.7%) and rash (6.6%); grade ≥ 3 events were observed in only 1.5% (2/136), both in patients receiving concurrent methotrexate. Median rifapentine concentration was 21.8 mg/L (interquartile range [IQR], 14.8-28.4), and 91.9% of participants exceeded the model-informed 10 mg/L threshold. Body weight demonstrated a modest inverse correlation with rifapentine concentrations (ρ = -0.24; P = .005), accounting for only 7.1% of interindividual variability. CONCLUSIONS: Fixed-dose 1HP exhibited good tolerability and achieved acceptable completion rate in Chinese adult population. Pharmacokinetic results confirmed adequate rifapentine exposure across the studied weight range, lending support to fixed-dose 1HP for programmatic scale-up.
引用
- Zhan S, Liu W, Yang L, et al. Fixed-Dose Rifapentine-Isoniazid (1HP) for Tuberculosis Preventive Treatment in Chinese Adults: A Prospective Real-World Safety and Pharmacokinetic Study. Clin Infect Dis. 2026. PMID: 41973994. doi:10.1093/cid/ciag247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。